Malignant pleural mesothelioma co-opts BCL-X<sub>L</sub> and autophagy to escape apoptosis

Duo Xu<sup>1,2</sup>, Shun-Qing Liang<sup>1,2</sup>, Zhang Yang<sup>1,2</sup>, Haitang Yang<sup>1,2</sup>, Rémy Bruggmann<sup>3</sup>, Simone Oberhaensli<sup>3</sup>, Sabina Berezowska<sup>4</sup>, Thomas M. Marti<sup>1,2</sup>, Sean R. R. Hall<sup>1,2</sup>, Patrick Dorn<sup>1,2</sup>, Gregor J. Kocher<sup>1,2</sup>, Ralph A. Schmid<sup>1,2</sup> and Ren-Wang Peng<sup>1,2</sup>

Abstract

Escape from programmed cell death is a hallmark of cancer. In this study, we investigated the anti-apoptotic mechanisms and explored the therapeutic potential of BCL-2 homology domain-3 (BH3) mimetics in malignant pleural mesothelioma (MPM), a lethal thoracic malignancy with an extreme dearth of treatment options. By implementing integrated analysis of functional genomic data of MPM cells and quantitative proteomics of patients' tumors, we identified BCL-X<sub>L</sub> as an anti-apoptotic driver that is overexpressed and confers an oncogenic dependency in MPM. MPM cells harboring genetic alterations that inactivate the NF2/LATS1/2 signaling are associated with increased sensitivity to A-1155463, a BCL-X<sub>L</sub>-selective BH3 mimic. Importantly, BCL-X<sub>L</sub> inhibition elicits protective autophagy, and concomitant blockade of BCL-X<sub>L</sub> and autophagic machinery with A-1155463 and hydroxychloroquine (HCQ), the US Food and Drug Administration (FDA)-approved autophagy inhibitor, synergistically enhances anti-MPM effects in vitro and in vivo. Together, our work delineates the molecular basis underlying resistance to apoptosis and uncovers an evasive mechanism that limits response to BH3 mimetics in MPM, suggesting a novel strategy to target this aggressive disease.

Introduction

Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy that is etiologically associated with asbestos exposure<sup>1,2</sup>. Despite the restriction of asbestos use in most countries, the incidence of MPM is still rising due in part to the long latency (around 40 years) of the interval from carcinogen exposure to tumor onset<sup>3</sup>. There are no typical clinical symptoms of mesothelioma in the early phase, and the majority of patients (80%) are diagnosed at advanced stages associated with extremely poor prognosis<sup>4</sup>. Previous studies in MPM have revealed frequent oncogenic events enabled by genetic alterations that inactivate tumor suppressor genes, most often BRCA1 associated protein-1 (BAP1), neurofibromatosis type 2 (NF2), large tumor suppressor kinase 2 (LATS2), and cyclin-dependent kinase inhibitor 2 A/2B (CDKN2A/2B), which, however, have proven difficult to be therapeutically exploited<sup>2,5,6</sup>. Further exacerbating the dilemma, platinum-based chemotherapy, the current standard of care for inoperable late-stage MPM, only marginally improves patient survival<sup>7</sup>. Hence, there is a pressing need to identify new druggable targets in MPM and develop effective therapeutic strategies for the daunting disease.

The NF2 tumor suppressor gene encodes Merlin (Moesin-ezrin-radixin-like protein), which mediates tumor suppression and contact-dependent inhibition by repressing Hippo, mTORC1, RAS, EGFR, and FAK-Src signaling pathways<sup>8</sup>. The Hippo signaling, an evolutionally conserved pathway that regulates organ size and...
tissue homeostasis by restricting cell growth and promoting apoptosis, is one of the best characterized Merlin/NF2-regulated pathways. Besides the mutation in NF2, other components of the Hippo pathway, e.g., large tumor suppressor kinase 1/2 (LATS1/2), are also frequently inactivated in MPM patients. Dysregulation of the Hippo pathway constitutively activates Yes-associated protein (YAP), a transcription regulator that promotes the transcription of genes involved in cell proliferation and anti-apoptosis by interaction with TEA/ATTS domain (TEAD) transcription factors.

Resistance to apoptosis, a critical barrier of tumor development, is one of the most prominent hallmarks of cancer. Overexpression of pro-survival B-cell lymphoma 2 (BCL-2) family members (BCL-2, BCL-XL, MCL-1, BCL-W,BCL-B, and BFL-1) is a key apoptosis evasion mechanism that promotes tumor growth by keeping pro-apoptosis effectors (BAX/BAK) in check. By contrast, the BCL-2 homology domain-3 (BH3)-only proteins (BAD, BIM, BID, NOXA, PUMA, BIK, BMF, and HRK) induce apoptosis neutralizing the pro-survival BCL-2 proteins. As such, targeting anti-apoptotic regulators with BH3 mimetics represents an attractive strategy for cancer therapy. Several BH3 mimetics, e.g., the BCL-2/BCL-XL/bcl-W inhibitor ABT-263 (navitoclax), BCL-2–selective inhibitor venetoclax (ABT-199), and BCL-XL–selective inhibitor A-1155463, have showed promising clinical activity. In particular, venetoclax has been approved by the US Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) with a 17p-deletion or TP53 mutation. We and others have reported that MPM cells can acquire anti-apoptotic adaptation as a protective mechanism to evade oncogenic stress and anticancer therapy. In this study, we systematically analyzed the cell survival dependency on anti-apoptotic BCL-2 proteins and explored the potential of specific BH3 mimetics as anti-MPM therapy.

Materials and methods

Cell culture and reagents

Human normal mesothelial cells (LP-9) was a gift from Robert Kratzke (Masonic Cancer Center, University of Minnesota, USA) and cultured in Medium 199 (Cat. #M7528; Sigma-Aldrich) supplemented with 15% fetal bovine serum (Cat. #10270-106; Life Technologies), 1% penicillin/streptomycin solution (Cat. #P0781, Sigma-Aldrich), 10 nM/ml of epidermal growth factor (Cat. #E5036, Sigma-Aldrich), and 0.4 μg/ml hydrocortisone (Cat. #07904, STEMCELL TECHNOLOGIES) at 37 °C with 95% air/5% CO2. Human normal lung fibroblasts (hFb16Lu;CCD-16Lu) and human MPM cell lines (Meso-1, Meso-4, JL-1, H2452, MSTO-211H, and H2052) were previously described. All cells were regularly tested free of mycoplasma (Microsynth), Armonycin A1 was provided by K. Krempaska (Department for Biomedical Research, University of Bern, Switzerland).

Cell viability and clonogenic survival assay

Cell viability was measured by acid phosphatase (APH) assay as described. Each data point was generated in triplicate from three independent experiments (n = 3). IC50 values were determined based on the best-fit curve generated in GraphPad Prism [log (inhibitor) vs. normalized response]. Combination Index (CI) was calculated by ComboSyn software. CI < 1.0, synergism; CI = 1.0, additive effects, CI > 1.0, antagonism. Clonogenic assay was done as described. Briefly, cells seeded in 6-well plates (1000–2000 cells/well) were treated for 96 h and cultured in the absence of drugs for 10–12 days depending on growth rate. The resulting colonies were stained with crystal violet (0.5% dissolved in 25% methanol).

Immunoblotting and immunohistochemistry

Cell lysates were prepared and immunoblot analysis was performed as described. In brief, protein lysates were resolved by SDS-PAGE (Cat. #4561033; Bio-Rad Laboratories) and transferred onto nitrocellulose membranes (Cat. #170-4158; Bio-Rad). After incubation with blocking buffer (Cat. #927-4000; Li-COR Biosciences) for 1 h at room temperature, membranes were incubated with primary antibodies (BCL-XL: 1:1000, Cleaved Caspase-7: 1:1000, Cleaved Caspase-3: 1:1000, Cleaved Caspase-9: 1:1000, Cleaved Caspase-12: 1:1000, Cleaved Caspase-8: 1:1000; Cell Signaling Technology) overnight at 4 °C. Membranes were washed and then incubated with secondary antibodies were visualized by the Odyssey Infrared Imaging System (Li-COR Biosciences), followed by quantification using Image J.

Immunohistochemical study were performed as described. In brief, surgically removed xenograft tumors (two tumors/group) were formalin-fixed, paraffin-embedded (FFPE), and stained with hematoxylin and eosin (H&E) using standard protocols. FFPE tissue blocks were sectioned at 4 μm, deparaffinized, rehydrated, and subsequently stained with appropriate antibodies (LC3B: 1:1000, Cleaved Caspase-3: 1:200; #9664, Cell Signaling Technology) using the automated system BOND RX (Leica Biosystems). Visualization was performed as described.
performed using the Bond Polymer Refine Detection kit (Leica Biosystems) as instructed by the manufacturer. Images were acquired using PANNORAMIC® whole slide scanners and processed using Case Viewer (3DHISTECH Ltd.). The staining intensities of the whole slide (two tumors/group) were quantified by QuPath software\textsuperscript{25}. 

**Apoptosis assay**

MPM cells were treated as specified in the figure legends. After treatment, cells in the supernatant and adherent to plates were collected, washed with PBS, and pooled before suspended in 400 μl binding buffer and stained with the Annexin V Apoptosis Detection Kit-FITC (Cat. #88-8005;
Therapeutic strategy (according to the manufacturer’s instructions). Flow cytometry analysis was performed on a BD Biosciences LSRII flow cytometer.

**Autophagic flux assay**

The mCherry-eGFP-LC3B lentivirus was kindly provided by Mario P. Tschan (Institute of Pathology, University of Bern, Switzerland). Briefly, lentivirus was transduced into cell lines followed by selection with puromycin (1 μg/ml) for 3 days and various treatments. Cells were then trypsinized and resuspended for flow cytometry analysis of GFP and mCherry fluorescence using a BD Biosciences LSRII flow cytometer. Data were analyzed by FlowJo software and gates for populations with low/intermediate/high mCherry/GFP ratio were set according to previous studies.

**Small interfering RNA (siRNA) knockdown**

Knockdown of BCL2L1 and ATG5 was achieved by specific duplex siRNAs (BCL2L1 siRNA, 15 nM; ATG5 siRNA, 30 nM) purchased from Origene Technologies (Cat. #SR319459 and SR322789). Transfection of siRNAs was performed with Lipofectamine 2000 (Cat. #116628027, Invitrogen) according to the manufacturer’s instructions.

**Animal experiments**

Mouse experiments were conducted in accordance with Institutional Animal Care and Ethical Committee-approved animal guidelines and protocols. Experiments were performed in 8-week-old male NSG (NOD−scid IL2Rγnull) mice, with sample size not predetermined by statistical method but rather based on preliminary experiments. Group allocation was performed in a randomized but not blinded manner. Suspensions of MEO-1 cells mixed 1:1 with Matrigel (Cat. #356231; Corning) were subcutaneously inoculated in the flanks (1 × 10⁶ cells/injection). One month after injection, mice were randomly assigned to treatment groups (n = 5): (1) control; (2) A-1155463 (5 mg/kg, i.p., once daily); (3) HCQ (50 mg/kg, i.p., once daily); (4) combination of A-1155463 and HCQ in the abovementioned doses (Tumor size was measured by digital caliper every two to three days. Tumor volume was calculated as follows: (length x width x width)/2). Mice were sacrificed at the end of 23-day treatment.

**Public databases (TCGA, TCPA, CBioPortal, DepMap, GEO, GSDC, and COSMIC)**

Interrogation of publicly available dataset was performed as we have described. Specifically, transcriptome profiling and reverse-phase protein array data of mesothelioma patients were obtained from the Cancer Genome Atlas (TCGA), the Cancer Proteome Atlas (TCPA), and the CBio Cancer Genomics Portal (CBioPortal). The catalog of gene essentiality across MPM cell lines is obtained from the Cancer Dependency Map Project (DepMap). Transcriptomic data of MPM samples (GSE2549) was downloaded from the Gene Expression Omnibus (GEO). Genomics of Drug Sensitivity in Cancer (GSDC) and Catalog of Somatic Mutations in Cancer (COSMIC) was used to extract transcriptomic data and mutation status of MPM cell lines.

**Statistical analysis**

Statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, Inc.). All samples that met proper experimental conditions were included in the analysis. Data represent biological replicates (n) and are
depicted as mean values ± s.d. or mean values ± SEM as indicated in the figure legends. Comparison of mean values was conducted with unpaired, two-tailed Student’s \( t \)-test, one-way or two-way ANOVA as indicated in the figure legends, \( P < 0.05 \) were considered statistically significant.
Results
BCL-X_L is deregulated and confers a survival dependency in MPM

In the attempt to explore the potential of BH3 mimetics as anti-PM treatment, we investigated genetic status, transcriptional expression, and dependency profile of the pro-survival BCL-2 gene family (BCL2L1, BCL2L10, BCL2, BCL2A1, BCL2L2, and MCL1) in MPM by interrogating TCGA dataset and functional genomics that determines genetic dependencies in cancers (DepMap; https://depmap.org/portal/). The integrated molecular characterization revealed that, of the anti-apoptotic genes, BCL2L1 (encoding BCL-X_L) is altered in a subset of MPM patients (n = 87), by means of gene amplification and mRNA overexpression (Fig. 1A) and MPM cells show the greatest dependency on BCL2L1 for survival (Fig. 1B, C). Consistently, BCL2L1 expression is significantly upregulated in patients’ MPM compared with that in normal pleural tissues (Fig. 1D). Our immunoblot analysis revealed upregulated expression of BCL-X_L in human MPM cell lines compared with normal lung fibroblasts (hFb16L1) and mesothelial LP-9 cells (Supplementary Fig. 1). Notably, a remarkably greater increase in BCL-X_L was observed in MPM cells compared with normal controls when BCL-X_L signal was normalized against Actin (loading control) and the total protein (Fig. 1E). Further supporting these observations, examination of TCPA dataset, which provides quantitative proteomics of patient-derived pan-cancers (n = 32), revealed that MPM had the third highest level of BCL-X_L (Fig. 1F). These results indicate that anti-apoptotic BCL-X_L is deregulated in MPM at genetic, transcriptional, and translational levels.

Next, we addressed whether BCL2L1 represents a genetic vulnerability in MPM. BCL2L1 knockdown by siRNAs caused significantly greater proliferative inhibition and apoptotic cell death in MPM cells (MESO-1, MESO-4, JL-1, H2452, MSTO-211H, H28, and H2052) than in LP-9 cells (Fig. 2A–D). Consistent with the genetic results, A-1155463, a potent and highly selective BCL-X_L inhibitor, preferentially impaired MPM cell proliferation, resulting in significantly greater growth inhibition in MPM cells than in LP-9 cells (Fig. 2E). Importantly, A-1155463 induced cleavage of caspase-7 (Fig. 2F) and a dose-dependent increase of apoptotic cells in MESO-1, as manifested by flow cytometry-based apoptotic analysis, which showed that treatment with 62.5, 125, and 250 nm A-1155463 resulted in 4+, 4.4-, and 5.4-fold increases in apoptotic cells (Annexin V-positive) compared with vehicle treatment (Fig. 2G). In contrast, A-1155463 treatment barely increased apoptosis compared with vehicle control in LP-9 cells (Fig. 2F, G). Importantly, the selective BCL-2 inhibitor Venetoclax failed to distinguish malignant from normal mesothelial cells, leading to almost equal effects on MPM and LP-9 cells (Supplementary Fig. 2A). Taken together, these results reveal that BCL-X_L is highly deregulated and confers an oncogenic dependency in MPM.

NF2/LAST1/2 mutations are associated with increased sensitivity to BCL-X_L inhibition in MPM

Next, we sought to identify potential biomarkers associated with MPM response to BCL-X_L inhibition in MPM. As expected, the BCL-X_L protein level was positively correlated with the sensitivity to A-1155463 [negatively with IC_{50} (50% inhibitory concentration)] in MPM cells (Fig. 3A, B).

It has been shown that cancer cells express high levels of anti-apoptotic proteins that, however, are constrained via heterodimerization by anti-apoptotic effectors during tumorogenesis. As a result, cancer cells can be considered to be ready to undergo apoptosis or “primed for apoptosis”, highlighting the potential of BH3 mimetics in the clinic. To explore a possible link of BCL2L1 with anti-apoptotic proteins in MPM, we examined a cohort of MPM patients (n = 127) in TCGA, which revealed that BCL2L1 mRNA level was positively correlated with that of several anti-apoptotic genes, e.g., BAX, BBC3, BIK, and BAK1 (Fig. 3C). Consistent with this observation, MPM cells that overexpress BCL-X_L also have higher protein...
levels of BAX (Supplementary Fig. 2B), suggesting that BCL2L1-positive MPM tumors are “primed” to apoptosis induction. By using a previously defined “primed for apoptosis” gene signature, determined by transcriptional expression of the pro-apoptotic genes (BAK1, BAX, BBC3, BID, BIK, BOK, and HRK)\textsuperscript{37}, we curated the “primed for apoptosis” score of H2452, MSTO-211H, H28, and H2052 cells, chosen for the availability of their transcriptomic
data in the Catalog of Somatic Mutations in Cancer (COSMIC). Our analysis revealed that MPM cells with higher scores of the apoptosis gene signature were more sensitive (lower IC₅₀ values) to A-1155463 (Fig. 3D), supporting the notion that expression of the pro-apoptotic genes predicts BCL-X₁ inhibition sensitivity.

Finally, we explored if recurrent genetic alterations in MPM are associated with sensitivity to BCL-X₁ inhibition. NF2/LATS1/2 loss of function (deletion, truncation, and mutation) is frequent (38%) in MPM (Fig. 3E), which downregulates YAP phosphorylation (YAP₁_pS127) and increases the activity of YAP oncoprotein (Fig. 3F). Consistent with this observation, MPM patients with low levels of YAP₁_pS127 (increased YAP activity) were associated with dismal prognosis (Fig. 3G) and MPM cells harboring NF2/LATS1/2 mutations/deletions exhibited increased sensitivity to A-1155463 (Fig. 3H). Supporting this finding, examining the TCGA cohort of MPM patients (n = 87) showed that NF2/LATS1/2-altered tumors were characterized by an increased BCL2L1 expression and “primed for apoptosis” score (Fig. 3I).

Thus, BCL-X₁ protein expression, “primed for apoptosis” gene signature and genetic alterations in NF2/LATS1/2 may serve as biomarkers to stratify MPM subsets that likely benefit from BCL-X₁ targeted therapy.

BCL-X₁ inhibition elicits protective autophagy in MPM cells

Our observations that MPM cells show heterogeneous responses to BCL-X₁ inhibition (Figs. 2, 3) suggest the existence of resistance mechanisms. This prompted us to explore the approaches to improve the efficacy of BCL-X₁-targeted therapy. Interrogation of TCPA dataset revealed SQSTM1 (sequestosome 1; also termed p62) as the top candidate that is significantly negatively correlated with BCL-X₁ (Fig. 4A). p62 is a key component of autophagic machinery functioning as a cargo adapter by physical interaction with and subsequent delivery of autophagic substrates to autophagosomes for degradation, suggesting a possible role for autophagy to protect MPM cells from the stress elicited by BCL-X₁ inhibition. Supporting our hypothesis, treatment with A-1155263 acutely increased autophagic activity in MESO-1 cells, marked by decreased p62, upregulated Beclin-1, and microtubule-associated proteins 1A/1B light chain 3B (LC3B)-II (Fig. 4B), whereby the conversion of cytosolic LC3B-I to autophagosome-localized LC3B-II is proportional with initiation of autophagy and therefore serves as a reliable marker of autophagosomes. Moreover, genetic (siRNAs) and pharmacological (A-1155463) inhibition of BCL-X₁ markedly increased the LC3B-II lapidated form, in particular the ratio of LC3B-II/Actin signal, compared with vehicle controls at the basal level and in the presence of Bafilomycin A1, an inhibitor of autophagosome-lysosome fusion, in a panel of MPM cells (Fig. 4C–F). In sharp contrast, the same effects of BCL-X₁ inhibition were not observed in LP-9 cells, as A-1155463 alone showed no effect on the LC3B-II/Actin ratio (compared with vehicle control), as did concomitant treatment with A-1155463 and Bafilomycin (compared with Bafilomycin alone) (Supplementary Fig. 2C). Importantly, using the mCherry-eGFP-LC3B fluorescence reporter, we showed that genetic and pharmacological inhibition of BCL-X₁ significantly increased the mCherry-GFP fluorescence ratio, a well-recognized measure of autophagic flux, in MPM cells stably expressing mCherry-eGFP-LC3B (Fig. 4G, H), further strengthening the notion that BCL-X₁ inhibition increases autophagy.

SQSTM1/p62 deregulation (e.g., mRNA upregulation or protein overexpression) occurred in a subset (9%) of MPM patients (Fig. 4I). Although implications of SQSTM1/p62 changes can be context-dependent and deserve cautious interpretations, the steady state level of p62 do reflect the autophagic status and it is widely accepted that impaired autophagy contributes to initiation and early development of cancer. Indeed, previous studies associated decreased p62 or high autophagy status...
with better clinical outcomes in MPM and other tumors.\textsuperscript{40,41} Supporting this notion, high p62 levels predicted poorer prognosis in MPM patients, opposite to the prognostic value of BCL-X\textsubscript{L} (Fig. 4), Supplementary Fig. S3A). Moreover, deregulation of SQSTM1/p62 and BCL2L1 appeared mutually exclusive (Fig. 4I), reiterating...
the reciprocal nature of p62-and BCL-X<sub>L</sub>-regulated processes in MPM development. Together, these results reveal that BCL-X<sub>L</sub> inhibition elicits autophagy, which may act as a compensatory mechanism that counteracts BCL-X<sub>L</sub> targeted therapy.

**Concomitant blockage of BCL-X<sub>L</sub> and autophagy synergistically enhances anti-MPM effects**

To test this hypothesis that autophagy protects MPM cells from the cytotoxicity of BCL-X<sub>L</sub> inhibition, MPM cells were concomitantly treated with A-1155463 and the autophagy inhibitor hydroxychloroquine (HCQ) across a broad range of concentrations. While single agents suppressed cell proliferation in a dose-dependent manner, A-1155463 plus HCQ produced a strong synergy, leading to significantly enhanced antiproliferative effects and apoptotic cell death in a panel of MPM cells, including NF2/LATS1/2-mutant and wild-type (Fig. 5A–E) but not in human normal lung fibroblasts (Supplementary Fig. S3B). The synergy also applied when HCQ was combined with ABT-263, a pan-inhibitor against BCL-2, BCL-X<sub>L</sub>, and BCL-W (Supplementary Fig. S3C–E).

To further explore the role of autophagy in MPM response to BCL-X<sub>L</sub> inhibition, we knocked down autophagy related 5 (ATG5), which encodes a key effector protein (ATG5) involved in the initiation of preautophagosome formation. Genetic depletion of ATG5 in MPM cells significantly enhanced the antiproliferative effects of BCL-X<sub>L</sub> inhibition (Fig. 5F, G), which is in line with the results of pharmacological studies (Fig. 5A–D). Thus, BCL-X<sub>L</sub> inhibition elicits protective autophagy and combined blockage of BCL-X<sub>L</sub> and autophagy represents a promising strategy to treat MPM.

**BCL-X<sub>L</sub> inhibition combined with hydroxychloroquine potently suppresses MPM growth in vivo**

To extend the in vitro observations to in vivo, we evaluated efficacy of the combination treatment with A-1155463 and HCQ in MESO-1 xenografts. Whereas A-1155463 alone delayed tumor growth, the addition of HCQ profoundly enhanced antitumor efficacy without obvious side effects, i.e., body weight loss (Fig. 6A–D). Immunohistochemical analysis demonstrated that tumors treated with A-1155463 alone showed enhanced punctate staining of LC3B (highlighted in insets) and reduced p62 compared with the vehicle group (Fig. 6E), consistent with an increase in the autophagic flux upon BCL-X<sub>L</sub> inhibition as we showed in vitro. Importantly, the combination treatment blunted A-1155463-elicited autophagy, accompanied by increase in tumor cell apoptosis as indicated by the increase in cleaved caspase-3 in the combination group compared with single treatment (Fig. 6E). Immunoblots indicated that drug combination of A-1155463 and HCQ increased p62 and cleaved caspase-7 compared with single agents alone (Fig. 6F), further supporting the notion that combined A-1155463 and HCQ suppresses autophagy and induces apoptosis. Overall, these in vivo data validate a novel therapeutic strategy by combined inhibition of BCL-X<sub>L</sub> and autophagy to target MPM.

**Discussion**

In this study, we showed that MPM capitalizes on BCL-X<sub>L</sub> for anti-apoptosis, and that NF2/LATS1/2 alterations and pro-apoptotic gene expression are associated with sensitivity to BCL-X<sub>L</sub> inhibition. We further revealed that BCL-X<sub>L</sub> blockage elicited protective autophagy, such that combined treatment with BCL-X<sub>L</sub>-selective BH3 mimetic and clinically approved autophagy inhibitor yields strong and synergistic anti-MPM effects in vitro and in vivo. Our data suggest the therapeutic potential of targeting BCL-X<sub>L</sub> alone for MPM subsets, and of co-targeting autophagy for unselected MPM.

Apoptosis is regulated by pro- and anti-apoptotic BCL-2 proteins, which is invariably deregulated in cancer. In response to oncogenic or stress signals, malignant cells overexpress anti-apoptotic proteins to dampen apoptosis by sequestering pro-apoptotic activators. In this scenario, cancer cells are proposed to be “primed” for
Fig. 5 Dual inhibition of BCL-XL and autophagy synergistically enhances antiproliferative effects and increases apoptosis. A, B Dose-response curves (A) of MPM cells treated with A-1155463 and HCQ, alone or in combination, for 96 h. Combination index (CI) values (B) were determined by the CompuSyn software. Data were shown as mean ± s.d. (n = 3). CI < 1.0, synergism; CI = 1.0, additive effects, CI > 1.0, antagonism. C Clonogenic assay of MPM cells treated for 96 h with A-1155463 and HCQ, alone or in combination. Cells were cultured without the drug for additional 12 days before crystal violet staining. Representative images of three independent experiments (n = 3) are shown. D Flow cytometry-based apoptosis assay of MPM cells treated with A-1155463 and HCQ, alone or in combination, for 48 h. Data were presented as mean ± s.d. (n = 3), with a representative plot shown in the left. *p < 0.05, **p < 0.01, ***p < 0.005, and ****p < 0.001 by one-way ANOVA with Sidak's multiple comparisons test. E Immunoblots of MESO-1 cells treated with A-1155463 and HCQ, alone and in combination, for 24 h. F, G MPM cells transfected with ATG5- or control siRNAs (siATG5, siCtrl) were analyzed (48 h post-transfection) by immunoblots (F) or treated with A-1155463 for another 24 h, followed by quantification of viable cells (G). Data were shown as mean ± s.d. (n = 3). *p < 0.05 and **p < 0.01 by unpaired t-test.
Fig. 6 Hydroxychloroquine (HCQ) potentiates anti-MPM efficacy of A-1155463 in vivo. A Development of MESO-1 xenograft tumors treated with the indicated drugs. Data were presented as mean ± SEM (n = 5). *p < 0.05, comparison between combination (A-1155463 plus HCQ)- versus A-1155463-treated group by two-way ANOVA with Tukey’s multiple comparisons test. **p < 0.01, comparison between combination-versus HCQ-treated group by two-way ANOVA with Tukey’s multiple comparisons test. B, C Tumor size (B) and weights (C) after the treatment. Data were presented as mean ± SEM (n = 5). *p < 0.05 and **p < 0.01 by unpaired t-test. D Mice body weights during the treatment. Data were presented as mean ± SEM (n = 5). E Immunohistochemical staining for LC3B, p62, and cleaved caspase-3 of MESO-1 xenograft tumors after the treatment. Quantiﬁcation of p62 and cleaved Caspase-3 in the entire tissue sections were performed by QuPath. F Immunoblots for LC3B, p62, and cleaved caspase-7 of MESO-1 xenograft tumors after the treatment. Protein quantiﬁcation is shown to the right.
apoptosis, as they accumulate sufficient amounts of the pro-apoptotic activators\textsuperscript{36}, which has engendered the concept of cancer treatment by conquering or overwhelming anti-apoptotic defenses, e.g., blockage of specific or multiple pro-survival proteins with BH3 mimetics such as ABT-263 (navitoclax) and ABT-199 (venetoclax)\textsuperscript{12,42}. In MPM, apoptosis suppression was reported to be promoted by defects in core-apoptosis signaling\textsuperscript{43}, and the pro-apoptotic BH3 mimetic ABT-737 targeting BCL-2/BCL-X\textsubscript{L}/BCL-W\textsuperscript{44} and a pan-BCL-2 inhibitor (JY-1-106) were active against MPM cells\textsuperscript{35,46}. However, despite the promising clinical activity of pan-BH3 mimetic drugs, challenges still prevail due to intrinsic or/and acquired resistance and on-target platelet toxicity\textsuperscript{14,47–49}, necessitating the need to dissect the survival dependency on individual BCL-2 proteins and the use of selective BH3 mimetics in clinical development. We show here that BCL-X\textsubscript{L} is a major survival dependency for MPM cells and that the BCL-X\textsubscript{L} by selective BH3 mimetic demonstrates therapeutic potential for subsets of MPM. Notably, our data are consistent with earlier observations that antagonizing BCL-X\textsubscript{L} by alternative strategies (e.g., antisense oligonucleotides) suppresses MPM cell survival\textsuperscript{44,50} and with the finding of a very recent study\textsuperscript{51} published amid the manuscript preparation of our work.

We showed for the first time that BCL-X\textsubscript{L} inhibition elicits protective autophagy that limits the efficacy of BCL-X\textsubscript{L}-selective BH3 mimetics. Autophagy and apoptosis constitute two important self-destructive processes to maintain cellular homeostasis\textsuperscript{52}, and there is a complex reciprocal interplay\textsuperscript{53–55}. Apoptosis activation can either increase or decrease autophagy, but the underlying mechanisms are controversial\textsuperscript{56}. Recent studies have reported that inhibition of pro-survival BCL-2 proteins with BH3 mimetics could induce autophagy either by releasing Beclin-1 from the BH3-binding groove of BCL-2/BCL-X\textsubscript{L} or by BAX- and BAK1-mediated LC3B lipidation\textsuperscript{57–59}. In line with this notion, we revealed that targeting autophagy with HCQ synergistically enhances the cytotoxic effect of A-1155463, suggesting that this combination may be a novel strategy for treating MPM. Notably and in further support of our findings, a recent report published amid the revision of this study showed that BCL-X\textsubscript{L} is overexpressed and is an important pro-survival protein in MPM cells\textsuperscript{50}.

The lack of therapeutically exploitable mutations has significantly hampered the development of targeted therapies for MPM\textsuperscript{24}, which, however, highlights the importance to identify oncogenic dependencies rather than specific driver mutations to combat MPM\textsuperscript{1}. We have systematically assessed the pro-survival BCL-2 proteins for their contributions to anti-apoptosis in MPM cells, which, to the best of our knowledge, has remained incompletely defined. Overall, our work demonstrates the therapeutic potential of BCL-X\textsubscript{L}-specific BH3 mimetics in MPM, alone and in combination with the FDA-approved HCQ.

Acknowledgements
The results published here are in part upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga. Robert Kritakze (Masonic Cancer Center, University of Minnesota, USA) and Mario P. Tschan (Institute of Pathology, University of Bern, Switzerland) are acknowledged for kindly providing LP-9 cells and lentiviral particles expressing mCherry-eGFP-LC3B, respectively. We thank Nivia Barontini (Thoracic Surgery Laboratory, Bern University Hospital), Kristina Krempaska (Department for Biomedical Research, University of Bern, Switzerland) for technical assistance.

Author details
1 Division of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland. “Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland. Interfaculty Bioinformatics Unit and Swiss Institute of Bioinformatics, University of Bern, Bern, Switzerland. 2Institute of Pathology, University of Bern, Bern, Switzerland

Author contributions
D.X., S.-Q.L., R.A.S., and R.-W.P. contributed to design, data acquisition, analysis, and interpretation; Z.Y., H.Y., R.B., S.O., S.B., T.M.M., S.R.R.H., P.D., and G.J.K. contributed to analysis and interpretation of data; D.X. drafted the manuscript and R.-W.P. critically revised the manuscript. All authors read and agreed on the final version of the manuscript.

Funding
This work was funded by grants from the Swiss Cancer League/Swiss Cancer Research Foundation (#KFS-4851-08-2019, to RWP). PhD fellowships from China Scholarship Council (to H.Y. and Z.Y.).

Ethics statement
The animal experiments were approved by the Veterinary Office of Canton Bern, Switzerland.

Conflict of interest
The authors declare no competing interests.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-03668-x.

Received: 13 March 2020 Revised: 22 March 2021 Accepted: 22 March 2021
Published online: 15 April 2021

References
1. Schepereel, A., Wally, F., Albelda, S. M. & Mundt, C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 19, e161–e172 (2018).
2. Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018).
3. Wu, L. et al. Progress of malignant mesothelioma research in basic science: a review of the 14th international conference of the international mesothelioma interest group (MIg2018). Lung Cancer 127, 138–145 (2019).
4. Rozsmai, M. et al. New perspectives on diagnosis and therapy of malignant pleural mesothelioma. Front. Oncol. 8, 91 (2018).
5. Guo, G. et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 75, 264–269 (2015).
6. Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407–416 (2016).
7. Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636–2644 (2003).
8. Li, W., Cooper, J., Karajannis, M. A. & Giancotti, F. G. Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep. 13, 204–215 (2012).
9. Yu, F.-X., Zhao, B. & Guan, K.-L. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163, 811–828 (2015).
10. Bemhameouch, S. et al. N2D/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev. 24, 1718–1730 (2010).
11. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
12. Merino, D. et al. BH3-mimetic drugs: blazed the trail for new cancer mediators. Cancer Cell 34, 879–891 (2018).
13. Fisic, S. W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5, 876–885 (2005).
14. Leeverson, J. D. et al. Exploring selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med. 7, 279ra240 (2015).
15. Stiegenbauer, S. et al. Venetoclax as a single agent for B-lymphoma subtypes: data from ongoing trials. Cancer Discov. 6, 1267–1277 (2016).
16. Chou, T. C. Drug combination studies and their synergy quantitation using the isobologram method. J. Pharmacol. Exp. Ther. 266, 50–58 (1993).
17. Soini, Y. et al. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-x, and bax in malignant mesothelioma. Clin. Cancer Res. 5, 3508–3515 (1999).
18. Xu, D. et al. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. Br. J. Cancer 101, 424–431 (2009).
19. Jacobson, B. A. et al. Activated 4E-BP1 represses tumourigenesis and IGF-I signaling in glioblastoma. Nature 485, 280–285 (2012).
20. Xu, D. et al. Endoplasmic reticulum stress signaling as a therapeutic target in malignant pleural mesothelioma. Cancers 11, 1502 (2019).
21. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440–446 (2010).
22. Xu, D. et al. CRSRP screening identifies WEHI as a combination target for standard chemotherapy in malignant pleural mesothelioma. Mol. Cancer Ther. 19, 661–672 (2020).
23. Schneider, C. A., Rasband, W. S. & Elcom, K. W. NIH image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).
24. Schaffer, A. M., Berezowska, S., Adams, O., Langer, R. & Tisch, M. P. Reliable LC3 and p62 autophagy marker detection in formalin-fixed paraffin embedded human tissue by immunohistochemistry. Eur. J. Histoch. 59, 2481 (2015).
25. Bankhead, P. et al. QuPath open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).
26. Parejo, S. et al. Assessing autophagy during retinoid treatment of breast cancer. J. Pathol. 242, 62–72 (2017).
27. Kinsey, C. G. et al. Protective autophagy elicited by RAF->MEK->ERK inhibition disrupts Bcl-xL and Mcl-1 protein-protein interactions with Bak. Mol. Cancer 12, 42 (2013).
28. Faber, A. C. et al. Mitosis inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov. 4, 42–52 (2014).
29. Oltersdorff, J. T. Attacking cancer’s Achilles heel: antagonism of anti-apoptotic BCL-2 family members. FEBS J. 283, 2661–2675 (2016).
30. Murai, M. C., Zalkov, E., Kimchi, A. & Kroemer, G. Self-eating and self-filling: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 8, 741–752 (2007).
31. Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D959–D961 (2013).
32. Tate, J. G. et al. COSMIC the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).
33. Liu, J. L. et al. Prognostic significance of p62/SQSTM1 subcellular localization and LC3B in oral squamous cell carcinoma. Br. J. Cancer 111, 944–954 (2014).
34. Tate, J. G. et al. Reliability of LC3B fluorescence microscopy as a measure of autophagy. Cell Death Discov. 6, 114 (2020).